2 not yet recruiting, 1 recruiting, 1 withdrawn. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Not yet recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
Follow cGVHD: new trials by email Literature Review of cGVHD trials Research Report on cGVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD Belumosudil, Sarilumab - cGVHD | Phase 1 | Not yet recruiting | Stanford University | 10 | 2026-09-01 | 2026-08-12 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). Gecacitinib - cGVHD, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2026-03-16 | 2026-03-17 |
| Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD Iguratimod - cGVHD | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | 20 | 2024-01-10 | 2026-09-30 |
| Belimumab for Treatment of cGVHD Following Allo-HCT Belimumab (Benlysta) - cGVHD | Phase 1 / Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 |
belimumab (1) · belumosudil (1) · iguratimod (1) · sarilumab (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · Stanford University (1) · Xuzhou Medical University (1) · xuna (1)
China (2)
Sally Arai, MD (1)